Top 5 Depression Apps for Primary Care Providers

Clinical and real-world data are on deck for lumateperone, seltorexant, and esketamine to treat major depressive disorder and treatment-resistant depression.

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

Lipocene expects to announce interim safety data from the study this quarter and said the phase 3 program results will support the company's NDA in 2026.

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

The risk for MDD is greatest in the first month after diagnosis and the absolute risk remains elevated even 20 years later, making early detection and treatment imperative.

In the RE104 group receiving the 30-mg dose, clinically meaningful reductions in the primary endpoint were seen on day 1 posttreatment and sustained through day 28 follow-up.